These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 12938797)
1. Improvement in hypertrophic cardiomyopathy after significant weight loss: case report. Uwaifo GI; Fallon EM; Calis KA; Drinkard B; McDuffie JR; Yanovski JA South Med J; 2003 Jun; 96(6):626-31. PubMed ID: 12938797 [TBL] [Abstract][Full Text] [Related]
2. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013 [TBL] [Abstract][Full Text] [Related]
3. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343 [TBL] [Abstract][Full Text] [Related]
4. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects. Madsen EL; Bruun JM; Skogstrand K; Hougaard DM; Christiansen T; Richelsen B Metabolism; 2009 Jul; 58(7):946-53. PubMed ID: 19409578 [TBL] [Abstract][Full Text] [Related]
5. The new role of pharmacotherapy for weight reduction in obesity. Fernstrom MH; Fernstrom JD Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983 [TBL] [Abstract][Full Text] [Related]
6. Effect of weight loss on P wave dispersion in obese subjects. Duru M; Seyfeli E; Kuvandik G; Kaya H; Yalcin F Obesity (Silver Spring); 2006 Aug; 14(8):1378-82. PubMed ID: 16988080 [TBL] [Abstract][Full Text] [Related]
7. Familial apical hypertrophic cardiomyopathy with aneurysmal evolution--an unusual form. Sá MI; Cabral S; Reis AH; Pereira LS; Oliveira F; Torres S; Gomes JL Rev Port Cardiol; 2006 Dec; 25(12):1147-55. PubMed ID: 17343104 [TBL] [Abstract][Full Text] [Related]
8. [Advanced sequelae of apical hypertrophic cardiomyopathy: report of two cases with wall motion abnormalities]. Kusukawa J; Suwa M; Nakayama Y; Hirota Y; Kawamura K; Adachi I; Akagi H J Cardiol; 1988 Mar; 18(1):259-69. PubMed ID: 3221316 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients. Chou KM; Huang BY; Fanchiang JK; Chen CH Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737 [TBL] [Abstract][Full Text] [Related]
10. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Krempf M; Louvet JP; Allanic H; Miloradovich T; Joubert JM; Attali JR Int J Obes Relat Metab Disord; 2003 May; 27(5):591-7. PubMed ID: 12704403 [TBL] [Abstract][Full Text] [Related]
11. Impact of body composition, fat distribution and sustained weight loss on cardiac function in obesity. Kardassis D; Bech-Hanssen O; Schönander M; Sjöström L; Petzold M; Karason K Int J Cardiol; 2012 Aug; 159(2):128-33. PubMed ID: 21367473 [TBL] [Abstract][Full Text] [Related]
12. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Muls E; Kolanowski J; Scheen A; Van Gaal L; Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595 [TBL] [Abstract][Full Text] [Related]
13. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K; J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224 [TBL] [Abstract][Full Text] [Related]
14. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Hendricks EJ; Greenway FL; Westman EC; Gupta AK Obesity (Silver Spring); 2011 Dec; 19(12):2351-60. PubMed ID: 21527891 [TBL] [Abstract][Full Text] [Related]
15. Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. Chanoine JP; Richard M Int J Pediatr Obes; 2011 Apr; 6(2):95-101. PubMed ID: 20858149 [TBL] [Abstract][Full Text] [Related]
16. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up. MacLaughlin HL; Cook SA; Kariyawasam D; Roseke M; van Niekerk M; Macdougall IC Am J Kidney Dis; 2010 Jan; 55(1):69-76. PubMed ID: 19926371 [TBL] [Abstract][Full Text] [Related]
17. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Harrison SA; Fecht W; Brunt EM; Neuschwander-Tetri BA Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049 [TBL] [Abstract][Full Text] [Related]
18. Low HDL predicts differential blood pressure effects from two weight-loss approaches: a secondary analysis of blood pressure from a randomized, clinical weight-loss trial. Turer CB; Bernstein IH; Edelman DE; Yancy WS Diabetes Obes Metab; 2012 Apr; 14(4):375-8. PubMed ID: 22059803 [TBL] [Abstract][Full Text] [Related]
19. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Rissanen A; Lean M; Rössner S; Segal KR; Sjöström L Int J Obes Relat Metab Disord; 2003 Jan; 27(1):103-9. PubMed ID: 12532161 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials. Czernichow S; Lee CM; Barzi F; Greenfield JR; Baur LA; Chalmers J; Woodward M; Huxley RR Obes Rev; 2010 Feb; 11(2):150-8. PubMed ID: 19573052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]